Technology · Biotechnology R&D expenditure

Biotechnology R&D expenditure in USA in 2026

US spending on biotechnology research and development in 2026 is 30 B $, ranking 1st. However, the real picture is different: American corporations like Amgen and Gilead Sciences invest tens of billions in new drugs and gene therapy. The zero figure likely reflects methodology—major investments flow through the private sector in Boston and San Francisco, not government programs.

Data for 2026 · unit: $
Position

USA world ranking

#1 / 197

Country position on the scale from last to first place for this indicator.

US
#1
#197#1
Trend

Change over time

Change in indicator over the available period.

15 B
1990
30 B
2000
20 B
2010
30 B
2020
28 B
2025
30 B
2026

Values — $

Related questions

People also search for

Other pages of the reference by this indicator.

Summary

Frequently asked questions

Biotechnology R&D expenditure in USA — how much?
Based on 2026 data — 30 B $. This is rank #1 out of 197 countries.
What is USA's rank by Biotechnology R&D expenditure?
USA ranks #1 out of 197 countries in the world ranking by «Biotechnology R&D expenditure».
How has Biotechnology R&D expenditure changed in USA?
Over the available period the indicator changed from 15 B to 30 B $.